MedPath

Repetitive Transcranial Magnetic Stimulation(rTMS) in the Treatment of Depression

Conditions
Major Depressive Disorder
Interventions
Device: repetitive Transcranial Magnetic Stimulation
Registration Number
NCT01198561
Lead Sponsor
Samsung Medical Center
Brief Summary

The objective of this study is to investigate the antidepressant efficacy of rTMS, and to assess cortical metabolism before and after rTMS sessions in patients with major depression. We also aimed to investigate differences between the responders and nonresponders to rTMS and what would predict clinical response to rTMS.

Detailed Description

The specific aims of this study is to: (1) evaluate the antidepressant efficacy of rTMS on major depression; (2) evaluate the effects of rTMS on cognitive function in depressive patients; (3) assess the effects of rTMS on cerebral glucose metabolism in depressive patients as measured by 18FDG PET; (4) investigate the differences of the regional cerebral glucose uptake changes during rTMS between responders and nonresponders to rTMS.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Twenty patients fulfilling the diagnostic criteria of major depression according to DSM IV will be enrolled in the study.
  • Antidepressant medication will be maintained throughout the study period.
Exclusion Criteria
  • Exclusion criteria are current neurological or other psychiatric disorders, as well as a history of epileptic seizures, substantial brain damage or neurosurgical operation, according to established safety criteria.
  • To exclude the effect of drug changes on post-rTMS cerebral glucose metabolism, the combinations and dosage of pre-rTMS antidepressant drugs will remain unchanged until the post-rTMS 18FDG PET is done.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
repetitive Transcranial Magnetic Stimulationrepetitive Transcranial Magnetic Stimulationrepetitive Transcranial Magnetic Stimulation is a depressive patient group treated with rTMS
Primary Outcome Measures
NameTimeMethod
Hamilton depression rating scale (HAM-D 17)baseline, 1, 2, and 4 weeks after TMS

measuring instrument of severity of depressive symptoms

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Samsung Medical Center

🇰🇷

Seoul, Kangnam-Ku, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath